Law & Regulation

US financial regulators have charged 69 firms for breaking new corporate laws brought in after a wave of scandals. Read More

The U.S. Securities and Exchange Commission has charged four more former Nortel Networks Corp. executives with accounting fraud, alleging they manipulated reserves to change Nortel's earnings statements on the orders of more senior officers of the Canadian networking equipment maker. Read More

When the Securities and Exchange Commission came under congressional fire this year for its handling of an insider trading probe into hedge fund Pequot Capital, Senator Charles Grassley said the episode showed that whistle-blowers were "as welcome as a skunk at a picnic". Read More

This report finds that goods manufactured in the US and sent to other countries do not meet our own safety standards and often do not receive media attention. Read More

Stepping up its campaign to shed light on the mysteries of executive pay, the Securities and Exchange Commission has sent letters to nearly 300 companies across America critiquing disclosures in this year's proxy statements and demanding more information. Read More

Federal regulators have turned down a request from Monsanto Co. to take action against dairy companies that advertise milk as free of synthetic hormones. Read More

Europe seems set for US-style controls on lobbying after the biggest public affairs companies in Brussels ruled out voluntary regulation because they would have to divulge their clients and fees. Read More

The Justice Department crackdown on corrupt practices overseas ensnares both U.S. and foreign companies Read More

A television documentary has uncovered flaws in a series of carbon offsetting schemes intended to make good the global warming gases emitted by flights and other polluting activities. Read More

Cancer patients in India have reason to be relieved at a high court ruling this week which dismissed a petition by Swiss pharmaceuticals multinational corporation (MNC) Novartis challenging an Indian law which denies patents for minor or trivial improvements to known drugs. Read More